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Abstract
Taking into consideration all primary solid tumors, the liver represents the most
common site involved in distant metastasization, also due to its important blood
reception from the majority of digestive organs. Despite the abundant literature
and guidelines about colorectal liver metastases, there is still great debate about
the treatment strategy in the case of non-colorectal ones. Therefore, in this
chapter, we reviewed the treatment strategy and surgical indications for the most
frequent non-colorectal liver metastases. In the case of neuroendocrine hepatic
secondaries, the literature suggests that surgery should be always considered for
patients with resectable hepatic disease, as this treatment results more likely to offer
the best long-term outcome. For what concerns liver metastases from gastric cancer,
surgical approach should always be undertaken if indications are appropriate,
after a multidisciplinary discussion to plan an adequate multidisciplinary adjuvant
treatment, a proper patient selection, and the exclusion of additional secondary
tumors or extrahepatic metastases. Taking into consideration liver secondaries from
breast cancer and their chemosensitivity, in the absence of brain and lung lesions, it
can be considered a space for liver surgery, especially in the case of single lesions or
a maximum of two lesions with dimensions within 3 cm. However, as the number
of cancer survivors is progressively increasing and, with it, the number of patients
affected by non-colorectal liver metastases, further randomized controlled trials are
required in order to better define the benefit of hepatic surgery in these kinds of
patients.
Keywords: Non-colorectal liver metastases, Non-colorectal hepatic metastases,
Metastatic neuroendocrine tumors, Metastatic breast cancer
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1. Introduction
Cancer metastasization is a highly selective, sequential, interdependent, nonrandom process
which causes transient or permanent changes in different genes at the DNA and/or mRNA,
creating a complex phenotype which favors the survival of a population of tumor cells within
an organ environment, distant from the primary tumor [1, 2]. This kind of complex process
usually requires many years in order to complete the great series of cumulative DNA changes
which consent neoplastic cells to metastasize. As the primary tumor growth may be very
slow and the metastasization process does not directly depend on primary tumor size, we
can observe two kinds of metastases based on the timing of their diagnosis: synchronous
metastases are defined as secondary lesions diagnosed within the first year after primary
tumor diagnosis, although this time, interval may vary in the literature between six months
and one year, while metachronous metastases are usually diagnosed after one year from the
primary tumor diagnosis.
Taking into consideration all primary tumors, the liver represents the most common site
of the distant metastases. This particular affinity for distant metastases may have different
explanations. First, it may be attributable to the site specificity patterns of neoplastic cells
from various primary cancers, which found the liver as the adequate soil where to seed their
circulating neoplastic cells [3, 4]. Furthermore, the liver receives 30% of the whole cardiac
output, second only to the kidney for the quantity of blood which every day will perfuse its
parenchyma, and is consequently more susceptible to neoplastic cell attachment. Moreover,
anatomical or mechanical considerations, such as the efferent venous blood stream or the
loco-regional lymphatic drainage, may be strongly responsible for this preference in the
metastasization site [5]. In fact, most intra-abdominal cancers, and in particular those which
originated in the digestive tract, result in having a great affinity for liver metastasization.
In spite of the great progresses of surgical techniques against the primary tumors, as well
as the improvement of adjuvant therapies, metastatic disease continues to be the greatest
challenge for the medical and the surgical oncologists. In fact, metastases are well recognized
as being the major cause of death among neoplastic patients, and the prognosis of patients
affected by unresectable liver metastases is very poor. However, although once metastatic
malignancies were commonly considered as a terminal neoplastic stage, nowadays, many
different therapeutical options have been introduced in order to provide a safe and efficient
treatment for these kinds of patients and improve both their quantity and quality of life [6–9].
Despite the abundant literature about colorectal liver metastases and the existence of a
great number of guidelines about this argument, there is still great debate about the
treatment strategy in the case of non-colorectal ones and controversies especially about
the management of rare liver secondaries. On the other hand, a recent review about
non-colorectal non-neuroendocrine liver metastases demonstrated surgery to be a benefit for
these kinds of metastatic patients, especially for those affected by primary testicular, ovarian,
and renal cell cancers but also for women with isolated breast cancer metastases to the liver
[10].
Obviously, patients affected by rare hepatic metastases should be conveyed into bigger
and more experienced centers, which could be able to more appropriately treat this kind
of disease. However, metastatic patients are always more numerous – thanks to the
improvement of chemotherapy and the introduction of targeted biological drugs – and
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deserve as many chances of treatment as possible in order to continue their long battle
against cancer. In this chapter, we will then discuss indications and timing of surgery in
cases of the most frequent non-colorectal liver metastases.
2. Liver Metastases from Neuroendocrine Tumors
Neuroendocrine tumors (NETs) include a heterogeneous group of neoplasms with different
origins and biological behaviors [11–13]. They are commonly distinguished into two classes
based on their primary origin: pancreatic neuroendocrine tumors (also known as islet cell
tumors) and gastrointestinal neuroendocrine tumors (also known as carcinoids) [14–16].
The widely promulgated benignity of these neoplasms has been more times brought into
question, due to the high prevalence of distant metastases and recurrences, and the current
literature recognizes nowadays their malignant potential [12, 17–24]. In particular, the recent
classifications of the 7th American Joint Committee on Cancer/Union Internationale Contre
le Cancer (AJCC/UICC) 2009 and of the European Neuroendocrine Tumor Society (ENETS)
2006, associated with the WHO classification 2010, classified NETs into well-differentiated
neuroendocrine tumors (low and intermediate grade based on the Ki67 labeling index, also
named NET-G1 or carcinoid and NET-G2, respectively) and into the group of neuroendocrine
carcinomas (high grade, poorly differentiated, also named NEC) [21].
Despite their rarity, liver metastases from NETs are not an infrequent finding, because they
are usually characterized by a very slow growth pattern and diagnosed in advanced stages
[9, 15, 25–29]. In particular, NETs present with liver metastases in even the 50–75% of cases
[30–32]. In an analysis of Modlin and colleagues on 13,715 patients, synchronous distant
metastases were already evident in 12.9% of patients with gastrointestinal NETs, whose
5-year overall survival rate resulted 67.2% [13].
The occurrence of hepatic secondaries is one of the most important prognostic factor
for survival [9, 21, 33, 34]. In fact, although for patients with unresectable liver
disease, biotherapy with somatostatin analogues, peptide-mediated radioreceptor therapy,
transarterial chemoembolization, selective intra-arterial radiotherapy, or new molecular
target-directed therapy can be employed [16, 35, 36], these therapies are considered as
palliative.
The role of liver surgery for patients with liver metastases from gastrointestinal NETs remains
to be an argument of great debate. In particular, the very small number of patients affected
by NETs explains the lack of randomized control trials in order to better define the role
of surgery in these rare cases. Moreover, the usually inert growth of NETs and their
long-term natural history make even more difficult to assess the real effectiveness of hepatic
surgical approach on their overall survival. Furthermore, it is well known that in most
patients, neuroendocrine liver metastases recur after hepatic resection in up to 70–94% of
cases at 5 years [21, 24, 25, 33, 37–39], the liver is the most common site of progression
of disease (69%) [35], and data on repeat liver directed surgery for recurrent disease have
been extremely limited and controversial [36]. In particular, in a study of Saxena and
colleagues, most patients with hepatic metastases from NETs experienced treatment failure
after liver resection. In particular, 57 patients (79%) developed disease progression at a
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median time of 23 months, and the liver represented the most common site of progression of
disease (69%) [23]. In another multi-institutional study on 339 patients, Mayo and colleagues
demonstrated that the majority of liver metastases from NETs came from carcinoid (53%)
and, at 5 years after surgery, their recurrence rate was 94% [38]. Therefore, the true curative
role of liver-directed surgery results is still very questionable.
A recent meta-analysis performed on five studies, considering 374 patients affected by
NETs liver metastases treated in a conservative manner and 161 treated with liver surgery,
demonstrated a significant increased survival in the group of patients treated with surgical
hepatic resections HR 0.45 (CI.95 0.34–0.60) in comparison to conservative treatments and
to embolization HR 0.34 (CI.95 0.21–0.55) [40]. All considered studies showed an increased
survival in the groups treated with complete surgical resection of liver metastases, but none
of the included studies were randomized so that the clinical evidence was low [21, 41, 42].
A systematic review considering 29 studies (between 1980 and 2009) found 5 years OS
of 70.5% (range 31–100%) and a 5-year progression-free survival of 29% (range 6–66%)
[43]. Histological grade, extrahepatic disease, and macroscopically incomplete resection
of liver metastases were associated with poor prognosis. In another multi-institutional
study evaluating 339 patients, Mayo et al. demonstrated at multivariate analysis that
synchronous disease, nonfunctional NET hormonal status, and extrahepatic disease were
the most important predictive factors of worse survival [36]. Concerning other prognostic
parameters for primary NETs and liver metastases, Katz et al. demonstrated that the robust
presence of tumor-infiltrating lymphocytes is a significant predictor of outcome [44]. Other
recent articles confirmed surgical therapy to be the most efficient approach against solitary
hepatic metastases [7, 8, 14, 22, 23, 33, 34, 40, 45, 46], with a potential curative resection
of liver secondaries can be undertaken in 13.7 to 24.5% of patients with metastatic NETs
[47–49], and a significant reduction of carcinoid symptoms [43], but the majority of studies
focused exclusively on resection rather than combined-modality approaches with ablation or
chemotherapy.
Taking into consideration our institutional cases of liver metastases from NETs, including
52% of synchronous metastases and 48% of metachronous ones, the overall survival of
patients who underwent hepatic resections and OLT resulted, respectively, in 44.9% (95% CI
26.0–77.7%) and 50% (95% CI 12.5–100.0%) at 5 years [45]. The median number of resected
hepatic metastases was 3. Surgical radicalness (R0) was reached in 84% of cases. Recurrences
happened in 60% of patients, among which, 66.7% were intrahepatic and 33.3% extrahepatic.
Postoperative complications affected 12% of patients but required reintervention in a single
case.
In our opinion, surgery should be always considered for patients with resectable hepatic
disease, as this treatment results more likely to offer the best long-term outcome. All patients
should be considered for curative surgical treatment, but also palliative resection of liver
metastases can be suggested. The advantage that can be potentially achieved with surgery
is that of removing all gross diseases. In the future, new clinical and biological prognostic
factors could be of help for the better identification of those patients who might benefit from
hepatic surgical therapy.
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3. Liver Metastases from Gastric Cancer
Gastric cancer is the fourth most common cancer worldwide [50] and the second cause
of cancer-related death worldwide [50]. Despite the significant reduction of gastric cancer
incidence in the last 20 years, we observed an increase of advanced stages at diagnosis [51].
In Western Europe and Anglo-Saxon world, the incidence of hepatic metastases from gastric
cancer during the course of the disease results about 30%-50%, including both synchronous
and metachronous metastases [52, 53]. In particular, at the time of diagnosis, 35% of patients
present with evidence of distant metastases, and 4% to 14% have metastatic disease to the
liver [54–74], whereas metachronous metastases after curative gastrectomy are detected in
up to 25–30% of patients, 80% of which appear within the first 2 postoperative years.
Surgical treatment of hepatic metastases from gastric cancers remains to be an argument
of great debate [72, 75–78]. In fact, although many studies observed no survival difference
among patients submitted or not to liver surgery, in selected cases, an aggressive treatment
can achieve unexpected results [65–68, 70, 73, 74, 79–85]. Moreover, surgical approach is
not always possible, due to multiple hepatic metastases or the presence of extrahepatic
secondaries [52, 53], and only 0.4 to 1% of metastatic gastric cancer patients result in being
eligible for radical surgery [54, 56, 57, 86].
Resection of liver metastases from gastric cancer was initially indicated in patients with
synchronous metastases who have no peritoneal dissemination or other distant metastases
and in those with metachronous metastases without any other recurrent lesion [68] and
only if a complete resection of the metastases can be achieved without compromising
postoperative liver function [70]. Thereafter, Roh and colleagues supported surgery
indication only in cases of metastases in one lobe of the liver without peritoneal
dissemination, hilar node metastases, or distant metastases [64]. Recently, in accordance with
these findings, the Japanese Gastric Cancer Association revisited its treatment guidelines,
which in the case of stage IV gastric cancer recommend only chemotherapy, radiation,
palliative surgery, and best supportive care [87], in favor of surgery with curative intent
for potentially resectable M1 disease, including patients with resectable hepatic metastasis,
positive cytological examination of peritoneal washes, or swollen nodes in the para-aortic
region [88].
Unfortunately, if we review the current literature, hepatectomy was indicated in only 0.4% to
1% of gastric cancer patients with liver metastases, because most hepatic metastases from
gastric adenocarcinoma are multiple, bilateral, and combined with peritoneal or lymph
node metastases, which directly invade adjacent organs, so that finally very few patients
result as good candidates for liver surgery [89]. Moreover, surgical indications for liver
metastases of gastric origin must be carefully determined because of the biological, clinical,
and pathological aggressiveness of the disease [90, 91]. However, even if the percentage
of patients who may benefit from resection is probably small, the majority of authors
agree that the local treatment of hepatic metastases, compared to palliation or systemic
treatment, significantly improved overall survival among these patients [56]. In particular,
overall 5-year survival rate of gastric cancer metastatic to the liver ranges between 0 and
10% [58, 59, 92], whereas it rises up to 20% after curative hepatectomy in the literature
[64–68, 73, 93]. Furthermore, taking into consideration the only article about hepatic
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metastasis local re-treatment after recurrence, the authors found a survival advantage in
local treatment repetition [94].
In the current literature, many factors resulted in influencing the survival rate of
gastric cancer patients with hepatic metastases. In particular, the prognosis seems to
be significantly worsened by greater extent of hepatic involvement (H3) or macroscopic
peritoneal dissemination (P1) detected at surgical exploration, by greater number (>1) and
size of hepatic metastases in H1-2 and P0 patients [61, 62, 95, 96], by greater tumor size
(T4), nodal involvement (N+ independently by the extension of the metastatic spread) or
higher grading (G3) [63, 80, 97], and the timing of liver metastases diagnosis if metachronous
to the primary tumor diagnosis [68, 70, 91]. Therefore, these factors should be considered
as possible confounding factors in the future studies. In addition, considering all these
prognostic factors, some authors suggested the necessity to clearly identify the patients which
could benefit from surgical treatment, in order to offer a chance to cure the patients who have
good prognostic factors and to avoid overtreatment in case of absence of these factors [56].
Taking into account local procedures for hepatic metastases, no consensus about
standardized therapeutic regimen for metastatic gastric cancer has been achieved yet,
so that a variety of alternative, multidisciplinary therapies have been recommended by
clinical practice guidelines, including radiofrequency ablation (RFA) [86], transarterial
chemoembolization (TACE) [98], microwave coagulation therapy (MCT) [95], adjuvant
chemotherapy, molecular targeted therapy, or palliative supportive care [99–101]. In
particular, RFA, MCT, and TACE could additionally be used in the case of an isolated
metastasis in either half of the liver, in the absence of extrahepatic disease [102, 103]. For
example, in some series of patients treated by RFA, survival rates resulted similar to those
reported in the best surgical series [61, 104, 105].
In summary, if indications are appropriate, surgical approach in the case of hepatic
metastases from gastric cancer should always be undertaken, after a multidisciplinary
discussion, a proper patient selection, and the exclusion of additional secondary tumors
or extrahepatic metastases. Neoadjuvant chemotherapy, as well as other multidisciplinary,
adjuvant treatment modalities, may have a synergic role if combined with surgery. And in
particular, local interventional procedures, such as RFA, MCT, or TACE, may be useful in
selected patients.
4. Liver Metastases from Breast Cancer
Breast cancer is the most prevalent cancer among the female population worldwide, with a
peak of incidence after menopause. Despite the gradual reduction of locally advanced breast
cancers and the consensual increase of early breast cancer – thanks to the introduction of an
organized mammographic screening [106, 107] and the evident therapeutic improvement –
stage IV breast cancer continues to represent a fatal disease and its incidence does not seem
to reduce with the passing of years. The first explanation may be that distant metastasis
in the hematogenous way does not depend on tumor size nor on lymph node involvement,
which is usually an expression of metastasization in the lymphatic way. Secondly, groups of
patients who more frequently present distant metastasis from breast cancer do not usually
represent a screening target, such as young premenopausal women.
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Typical breast cancer metastasization sites are, in order of frequency, the bones, liver, lungs,
and brain. In our institutional casistic, distant metastasis prevalence among breast cancer
patients resulted about 10%, which in about the 20% cases are synchronous with the primary
cancer diagnosis, whereas the remaining 80% of women developed metachronous metastasis.
In the context of the incidence of distant metastases, hepatic ones vary from 5 to 34% [108–
111], with values rising up to over 60% in autopsy series [112]. The prognosis is poor in
this area being the median survival of 1–20 months from the diagnosis of liver metastases
[108, 109, 113, 114]. Long survivals seem to be related to a positive endocrine treatment
response, performed in the subgroup of patients with positive estrogen receptor pattern,
with median survivals around 14 months compared to 4 months in the other cases [114].
Overall, with current chemotherapy regimens, survivals ranging from 1 to 25 months are
obtained. However, after discontinuation of chemotherapy, only 40% of cases are responsive
to the same regimen.
Studies on the outcome of local treatment currently do not offer univocal results, probably
because of possible selection bias of cases operated and/or treated with other modalities
such as thermal ablation, destruction with yttrium, or chemoembolization. On average, in
the cases undergoing liver resection, the median survival is of 27–63 months. In almost all
studies, however, there is a subgroup of patients with very encouraging survival responses,
and many efforts have been directed toward the identification of the related prognostic
factors. At the moment, it seems that the receptor status of the primary tumor, the value
of Ki-67, the number of liver lesions removed, resection margin, and menopausal status may
play a positive role on prognosis [115]. However, the proportion of patients that presents the
favorable characteristics is small, not exceeding 3% of patients [116].
Over the past 20 years, the survival of patients with stage IV has been gradually improving
as a function of new chemotherapy regimens, local control with radiation therapy, and
other forms of intervention. As previously stated, the metastatic breast cancer involves
with a high frequency the bones, lungs, liver, and brain. Individually or predominantly
considered within the concept of "oligometastatic state," each of these sites leads to different
outcomes with median survival of 43 months for nodal involvement, 33 months for metastatic
bones, 22 months for the lung, and 12 months for liver. For multiple sites of metastases or
brain metastases, survival values collapse, respectively, to 9 and 3 months [117]. Given
the prognostic value represented by each metastatic site, the meticulous choice of the
liver resection candidate is obvious. In fact, in the studies that show the reference global
population, the rate of resection is absolutely modest, around 0.3%, but with a high resection
rate, 81%, being the non-resected cases due to intraoperatively carcinomatosis diagnosis
[118–120].
In the most recent and representative case studies series, resection of breast cancer liver
metastases shows that the appearance of metastases follows the discovery of the primary
tumor of an average of 40 months (23–77), the indication for resection concerns cases with
single lesion or a maximum of two lesions, with dimensions within 3 cm in most cases,
and that in most cases, major resections were performed (more than 3 liver segments) with
values of radical resection (negative margin resection) of more than 80% [118–125]. The
average survival values reported by these series range from 32 to 74 months and the 5-year
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follow-up survival rates are of 34–80%. Interestingly, the rates of postoperative mortality are
of 0% and morbidity of 0–44% that make absolutely acceptable the surgical treatment in these
cases thus selected. Prognostic factors evaluated in multivariate methods ultimately lead to
the conclusion that the only real risk factor is represented by the positive resection margin.
Considering these results and taking into account the chemosensitivity of breast cancer
emerges the consideration that even in cases of more consistent hepatic invasion, in the
absence of brain and lung lesions, it can be considered a space for liver surgery [126]. It is
evident from many series that survival is influenced by the state of the free margin, although
not always the gap between R0 and R1 leads to a robust statistical difference [122]. Therefore,
considering the possibility of a chemotherapy response and the greater possibility of surgical
treatment also linked to the impact of new intraoperative technologies (e.g., radio frequency
and microwave), it seems natural to expect in the immediate future an expansion of the
surgical indications for breast cancer liver metastasis.
As a paradigm of these considerations, we take as example the case of a woman who after two
breast surgeries for two metachronous cancers underwent chemotherapy for the appearance
of liver metastases, with partial response, followed by rupture of one of the lesions and
therefore emergency surgery for hemoperitoneum. Subsequently, after about six months,
she developed a second hemoperitoneum treated again by surgical hemostasis. Afterward,
she was transferred to our center and it was then made with palliative intent a major liver
resection, left hepatectomy en bloc with part of the stomach and removal of two peritoneal
implants. In the same intervention, the other two lesions on the right liver lobe were not
treated. These two lesions were later treated by radiofrequency ablation combined with
transcatheter arterial chemoembolization. Surprisingly the patient is alive and disease-free
43 months after the last procedure.
5. Conclusive Summary
Thanks to the improvement in the diagnostic and therapeutic pathways, the number of
cancer survivors is progressively increasing, as well as the number of metastatic patients.
Taking into consideration all primary solid tumors, the liver represents the most frequent
site involved by distant metastasization, also due to its anatomical position and its important
blood reception from the majority of digestive organs.
Despite the abundant literature and guidelines about colorectal liver metastases, there is
still great debate about the treatment strategy in the case of non-colorectal ones. Anyway,
many experiences have been published in the last decades about surgical treatment of the
most frequent non-colorectal liver metastases. In particular, we reviewed surgical strategies
in the case of hepatic secondaries from neuroendocrine tumors, gastric cancer, and breast
cancer. And in every case, the literature suggests a role for hepatic surgery for patients with
resectable hepatic disease.
However, the number of considered patients is often very limited as well as the statistical
strength of the current literature. Therefore, further randomized controlled trials are required
in order to better define the benefit of hepatic surgery in these kinds of patients.
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